# q01 rev 3 - local removal probe without D05 (platform Doc 6), 2026-10-06

Design evidence, not a blind solve. Fresh blind-solver on packet runs/q01-r3-probe-n4/solver-1:
a byte copy of the rev 3 solver-1 packet minus D05, remaining ids renumbered contiguously
(probe D05 = D06), neutral run name, bound with docket_agent.bind_scope. Prompt: root, packet,
verbatim rev 3 question, plus a forced best answer with probability.

Raw return as received (probe ids):

I found no closing date in the packet, so this is a forced best answer. My answer is **high-single-digit growth** for "Other", from the guidance Cencora issued on May 6, 2026. I put the probability that this is correct at about 0.55. The packet shows the unit had not been reported as sold by May 6, 2026, which points to a closing after that update.

answer: High-single-digit growth in fiscal 2026 adjusted operating income for "Other" (FY2025 actual base: $352M). Forced best answer; probability correct about 0.55.

confidence: low

path:
1. **Which category held the unit.** D05, line 121 (Nov 5, 2025): "The U.S. Healthcare Solutions reportable segment will consist of U.S. Human Health (excluding legacy U.S. Consulting Services)… Other, which is not considered a reportable segment… includes MWI Animal Health, Profarma, U.S. Consulting Services…" D03, line 86 (May 6, 2026) still says "These businesses include MWI Animal Health, Profarma, U.S. Consulting Services, and certain components of PharmaLex." So the category is Other. It is not a reportable segment, which fits the question's wording "reporting category".
2. **Guidance for Other's adjusted operating income over time:**
   - D05, line 138 (Nov 5, 2025): "1% to 4% decline", $352M base.
   - D01, line 114 (Feb 4, 2026): "Flat". The reason given at line 103 is "improved results in Other as certain depreciable assets have been fully impaired as of December 31, 2025."
   - D03, line 123 (May 6, 2026): "High-single digit growth". The reason given at line 112 is "updated operating income expectations in Other as a result of MWI now being accounted for as 'held for sale'."
3. **The packet never dates the closing, but it limits when it could have happened:**
   - D01, line 47: the unit "is classified as held for sale", with a $249.5M impairment. It was not sold as of Dec 31, 2025.
   - D03, line 102: Q2 results for Other cite "a decrease in sales at our consulting services businesses." This reads as a business still operating, not one that had been sold.
   - The six-month reconciliation in D03 (lines 356–371) has no gain or loss on a divestiture. The only such line is the fiscal 2025 "Loss on divestiture of non-core businesses" (line 415).
   - The D03 "Recent Company Highlights & Milestones" (lines 104–108) list only the MWI/Covetrus agreement and the EyeSouth deal. The guidance comments mention only MWI being held for sale.
   - So the closing most likely came after May 6, 2026. Unless a later update (not in the packet) replaced it, the May 6 guidance was in effect at the closing: high-single-digit growth.
4. No calculation is needed. The answer is a printed qualitative range, not a percentage.

minimal_documents: D03 alone states the category's membership, that the unit was still held for sale, and the guidance row. D01 and D05 are needed only for the alternative readings and to rule out a closing before Feb 4. D02 and D04 cover fiscal 2025 guidance and do not matter here.

readings:
- **Closing between Feb 4 and May 5, 2026** (for example, April 2026, simply not mentioned in the May 6 release): the answer would be **"Flat"** (D01). I put this at about 0.25–0.3.
- **Closing before Feb 4, 2026:** the answer would be **"1% to 4% decline"** (D05). D01's "is classified as held for sale" argues against this; about 0.05.
- **Closing after Cencora's next quarterly update (expected around August 2026):** that update is not in the packet, so the answer can't be determined if it changed Other's guidance; about 0.1–0.15.
- **Reading the category as U.S. Healthcare Solutions** (where U.S. Consulting sat in fiscal 2025): D05 explicitly excludes the unit from that segment for fiscal 2026, so this reading is rejected.

gaps:
- No document gives the closing date or any closing announcement. Searches for consulting, divest, closed/completed, sold, proceeds, Xcenda and dates from April to August 2026 found nothing. The fiscal Q3 2026 release, any later guidance and any closing 8-K are not in the packet.
- Coverage: I read D01 and D03 in full, D05 lines 1–200 (the rest only through searches), D04 lines 73–124, and D02 only through searches.
- The text extraction lost the bold formatting that marks updated guidance rows (D03 note 1). The Q2 changes are clear from comparing the D01 and D03 tables anyway.
- The packet files are text sources (manifest "pages": null), so there were no PDF pages to check.

contaminated: no

Caller note: forced best answer "High-single digit growth" (p 0.55), Flat 0.25-0.3: off the gold,
consistent with the rev 1 and rev 2 probes.
